Oak Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Hold
1,170
0.07% 92
2025
Q4
$1.26M Sell
1,170
-24
-2% -$22.9K 0.08% 92
2025
Q3
$911K Buy
+1,194
New +$889K 0.06% 97
2023
Q1
Sell
-5,740
Closed -$2.1M 142
2022
Q4
$2.1M Buy
+5,740
New +$2.04M 0.18% 85
2017
Q4
Sell
-22,500
Closed -$1.93M 160
2017
Q3
$1.93M Hold
22,500
0.14% 95
2017
Q2
$1.85M Hold
22,500
0.14% 99
2017
Q1
$1.89M Hold
22,500
0.15% 100
2016
Q4
$1.66M Hold
22,500
0.16% 99
2016
Q3
$1.66M Hold
22,500
0.17% 101
2016
Q2
$1.77M Sell
22,500
-3,200
-12% -$241K 0.21% 97
2016
Q1
$1.85M Sell
25,700
-1,800
-7% -$136K 0.23% 89
2015
Q4
$2.32M Hold
27,500
0.28% 79
2015
Q3
$2.3M Sell
27,500
-500
-2% -$42.2K 0.31% 76
2015
Q2
$2.34M Sell
28,000
-1,400
-5% -$107K 0.28% 81
2015
Q1
$2.14M Sell
29,400
-1,500
-5% -$107K 0.26% 88
2014
Q4
$2.13M Sell
30,900
-500
-2% -$33.8K 0.26% 87
2014
Q3
$2.04M Hold
31,400
0.25% 83
2014
Q2
$1.95M Sell
31,400
-1,500
-5% -$89.5K 0.24% 88
2014
Q1
$1.94M Hold
32,900
0.24% 87
2013
Q4
$1.68M Buy
+32,900
New +$1.65M 0.18% 94
2013
Q2
$1.62M Buy
+32,900
New +$1.79M 0.19% 87

Other funds holding LLY

Oak Associates's LLY Position: Q1 2026 in Review

Oak Associates held its Eli Lilly (LLY) position steady in Q1 2026 at 1,170 shares worth $1.08M. The position accounts for 0.07% of the portfolio, ranked #92.

Oak Associates first reported a position in LLY in Q2 2013 and has held it in 21 quarters since. The position peaked at $2.34M in Q2 2015. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Oak Associates held 1,170 shares of Eli Lilly worth $1.08M as of Q1 2026.
  • Oak Associates left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 0.07% of Oak Associates's portfolio in Q1 2026, its #92 holding.
  • Oak Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 21 quarters since.
  • Oak Associates's Eli Lilly position peaked at $2.34M in Q2 2015.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.